State of New Jersey Common Pension Fund D Has $3.45 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

State of New Jersey Common Pension Fund D lifted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 20.1% during the 4th quarter, HoldingsChannel reports. The fund owned 159,803 shares of the company’s stock after buying an additional 26,769 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Syndax Pharmaceuticals were worth $3,453,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SNDX. SG Americas Securities LLC acquired a new stake in shares of Syndax Pharmaceuticals in the third quarter worth $143,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Syndax Pharmaceuticals by 6.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,192 shares of the company’s stock worth $613,000 after buying an additional 2,700 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. acquired a new stake in Syndax Pharmaceuticals during the third quarter worth $1,663,000. China Universal Asset Management Co. Ltd. boosted its stake in Syndax Pharmaceuticals by 97.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,782 shares of the company’s stock worth $26,000 after buying an additional 880 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Syndax Pharmaceuticals by 5.1% during the third quarter. Teacher Retirement System of Texas now owns 15,619 shares of the company’s stock worth $227,000 after buying an additional 757 shares in the last quarter.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ SNDX opened at $21.06 on Friday. The business has a fifty day moving average of $22.67 and a two-hundred day moving average of $19.56. Syndax Pharmaceuticals, Inc. has a 52-week low of $11.22 and a 52-week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same quarter last year, the company earned ($0.62) earnings per share. As a group, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNDX has been the topic of a number of recent research reports. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Scotiabank downgraded shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and decreased their price target for the stock from $36.00 to $23.00 in a research note on Wednesday, January 31st. Finally, HC Wainwright reiterated a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.42.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).